EUVIMEDEUVIMED entdecken
Beobachtungsstudie

Efficacy of Hepatitis B Vaccination with a Novel Immunostimulatory Sequence Adjuvant (Heplisav-B) in Patients With Inflammatory Bowel Disease

Joshua Y Kwon iD, Nader D Daoud, Jana G Hashash iD, Michael F Picco, Francis A Farraye

Inflammatory Bowel Diseases · 2023

DOI: 10.1093/ibd/izac079 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Inflammatory Bowel Diseases, 2023. Verfasst von Joshua Y Kwon und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medicine, Mayo Clinic, Jacksonville, FL, USA. Hauptthemen laut MEDLINE: Colitis, Ulcerative, Crohn Disease, Hepatitis B, Hepatitis B Vaccines. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 50 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Owing to the use of immunosuppressive agents, patients with inflammatory bowel disease (IBD) have an increased risk of vaccine preventable diseases, including infection with hepatitis B virus (HBV). Heplisav-B, an FDA-approved vaccine, is more effective (90% to 100%) than Engerix-B (70.5% to 90.2%) at inducing immunity to HBV in clinical studies. Available data on efficacy of Heplisav-B vaccine in patients with IBD are limited.

Methods

This retrospective observational study included patients age 18 years and older with ulcerative colitis (UC) or Crohn’s disease (CD) who received 1 or 2 doses of Heplisav-B vaccine and had postvaccination serologic testing. Prior to immunization, all participants were seronegative for HBsAb antibodies (HBsAb) measured as <10 IU/mL. Postvaccination HBsAb of ≥10 IU/mL was considered successful vaccination. Patient demographics, disease characteristics, and medications were abstracted.

Results

One hundred six patients were included in the analysis. Median age was 43 years, and 44 (42%) were female. Thirty-nine patients (37%) had UC, whereas 67 (63%) had CD. Eighty-three patients (78.3%) had active immunity after vaccination with Heplisav-B, with median postvaccination HBsAb levels of 114 IU/L. Patients with chronic obstructive pulmonary disease, chronic kidney disease, diabetes mellitus, immunomodulator use, or those on 2 or more of immunosuppressive medications were less likely to respond to Heplisav-B, though these findings were not statistically significant on a multivariate analysis aside from chronic kidney disease.

Conclusions

Heplisav-B, a 2-dose vaccine, is an effective vaccine for HBV in patients with IBD. In our study, its overall efficacy (78.3%) is greater than that reported for the presently available 3-dose vaccination (Engerix) in patients with IBD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colitis, UlcerativeCrohn DiseaseHepatitis BHepatitis B VaccinesRenal Insufficiency, ChronicAdolescentAdultFemaleHumansMaleHepatitis B AntibodiesHepatitis B Surface AntigensHepatitis B virusImmunizationInflammatory Bowel DiseasesVaccinationVaccine Efficacy

Stichwörter der Autor:innen

CpG-1018Engerix-BHeplisav-Bhepatitis Bimmunityrecombinant vaccineseroconversionvaccination

Substanzen

Hepatitis B AntibodiesHepatitis B Surface AntigensHepatitis B Vaccines

Autor:innen und Institutionen

  • Department of Medicine, Mayo Clinic, Jacksonville, FL, USA.
  • Division of Gastroenterology and Hepatology, Mayo Clinic, Jacksonville, FL, USA.

ORCID-Profile: Joshua Y Kwon, Jana G Hashash

Zitieren

APA

Kwon, J. Y., Daoud, N. D., Hashash, J. G., Picco, M. F., & Farraye, F. A. (2023). Efficacy of Hepatitis B Vaccination with a Novel Immunostimulatory Sequence Adjuvant (Heplisav-B) in Patients With Inflammatory Bowel Disease. Inflammatory Bowel Diseases. https://doi.org/10.1093/ibd/izac079

Vancouver

Kwon JY, Daoud ND, Hashash JG, Picco MF, Farraye FA. Efficacy of Hepatitis B Vaccination with a Novel Immunostimulatory Sequence Adjuvant (Heplisav-B) in Patients With Inflammatory Bowel Disease. Inflammatory Bowel Diseases. 2023. doi:10.1093/ibd/izac079

BibTeX
@article{Kwon2023,
  author = {Kwon, Joshua Y and Daoud, Nader D and Hashash, Jana G and Picco, Michael F and Farraye, Francis A},
  title = {Efficacy of Hepatitis B Vaccination with a Novel Immunostimulatory Sequence Adjuvant (Heplisav-B) in Patients With Inflammatory Bowel Disease},
  journal = {Inflammatory Bowel Diseases},
  year = {2023},
  doi = {10.1093/ibd/izac079}
}
Kostenlos starten →